Acquisition Establishes Clinical and Operational Foundation for LifeMD's Comprehensive Women's Health Offering, Launching Summer 2025 LifeMD is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across more than 200 conditions, including primary care, men's and women's health, weight management, and hormone therapy. The Company leverages a vertically integrated, NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc ...

Core Insights - Progyny has appointed Melissa Cummings as the first Chief Operating Officer (COO) and Geoffrey Clapp as the first Chief Product Officer (CPO) to enhance operational excellence and innovation in women's health and family building [1][2] - The company serves over 530 leading employers, covering 6.7 million contracted lives, and continues to evolve its offerings, including the new Parent and Child Well-being program and doula support [4] Leadership Appointments - Melissa Cummings brings 30 years of healthcare experience, previously serving as Executive Vice President and Chief Customer Officer at Blue Cross & Blue Shield of Rhode Island [2][3] - Geoffrey Clapp has over two decades of experience in healthcare technology and product development, previously leading strategy at Optum Health Solutions [3][4] Company Vision and Strategy - Progyny aims to set a new standard in healthcare with its unique model and commitment to high-touch care, addressing care gaps in women's health [3] - The leadership team is focused on scaling Progyny's mission and impact, anticipating future member needs while delivering immediate value [4] Market Position - Progyny is recognized as a leader in women's health and family building solutions, trusted by major employers and health plans [6][7] - The company has received multiple accolades, including being named a TIME100 Most Influential Company and a CNBC Disruptor 50 [7][8]

Core Viewpoint - Daré Bioscience is advancing its business strategy to integrate 503B compounding for its proprietary Sildenafil Cream formulation, aiming to provide women with timely access to treatment options while pursuing FDA approval [2][3][4]. Financial Highlights - For the year ended December 31, 2024, Daré reported total revenue of approximately $9.78 million, a decrease from $2.81 million in 2023 [25]. - The company incurred total operating expenses of approximately $23.46 million in 2024, down from $33.75 million in the previous year, resulting in a net loss of approximately $4.05 million compared to a net loss of $30.16 million in 2023 [25]. - Cash and cash equivalents at the end of 2024 were approximately $15.70 million, an increase from $10.48 million in 2023 [26]. Product Development and Strategy - Daré plans to make its proprietary Sildenafil Cream formulation available via a 503B-registered outsourcing facility partner in the fourth quarter of 2025, targeting revenue generation from this product [2][4]. - The company is also focusing on a dual-path approach for other proprietary formulations, enhancing its portfolio diversity and potential revenue opportunities [2][3]. - Ongoing clinical studies include a pivotal Phase 3 contraceptive efficacy study for Ovaprene, with expectations to complete enrollment of approximately 125 women by the end of the second quarter of 2025 [9]. Research and Development - Research and development expenses for 2024 were approximately $14.2 million, a 34% decrease from the previous year, primarily due to reduced manufacturing activities and ongoing enrollment in clinical studies [25]. - Daré is preparing for a Phase 2 clinical study of DARE-HPV and a Phase 3 study of Sildenafil Cream, reflecting FDA feedback for safety and efficacy evaluations [9][10]. Market Position and Future Outlook - Daré aims to fulfill the urgent need for evidence-based treatment options in women's health, with a focus on innovative solutions that address unmet needs [18]. - The company anticipates starting to record revenue and cash flow from its Sildenafil Cream formulation in the fourth quarter of 2025, with updates on strategic partnerships expected in the second quarter of 2025 [2][4].